Celecoxib (Celebrex).

Celecoxib is a COX-2 selective NSAID used for pain and inflammation. It contains a sulfonamide group, and the U.S. label still lists a demonstrated allergic-type reaction to sulfonamides as a contraindication. Allergy specialists largely regard that contraindication as unsupported: celecoxib lacks the arylamine that drives sulfa antibiotic allergy, and measured cross-reactivity is low. But the labelling has not been withdrawn, and prescribing against a live contraindication is a judgement for your clinician, not a formality.

Educational reference — not medical advice. This page describes what is generally known about a drug family. It cannot account for your history, your other medicines, or your circumstances. Decisions about your own treatment belong with your doctor or pharmacist.

Class: COX-2 selective non-steroidal anti-inflammatory drug (NSAID).
Brand: Celebrex (most common); generic celecoxib widely available.
Common indications: Osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute pain, dysmenorrhoea.
Sulfa allergy: Still a labelled contraindication in the U.S. and EU as of the December 2024 U.S. label — though specialist guidance judges cross-reactivity to be low.

What it does

Cyclooxygenase (COX) enzymes convert arachidonic acid to prostaglandins, which mediate pain, inflammation, and fever. Two main isoforms exist: COX-1 (constitutive in many tissues, including the gastric mucosa, where its prostaglandins protect the stomach lining) and COX-2 (inducible, prominent at sites of inflammation). Celecoxib selectively inhibits COX-2 over COX-1.

The clinical aim of COX-2 selectivity was to retain the anti-inflammatory and analgesic effects of NSAIDs while reducing their gastrointestinal toxicity. Studies have largely supported a reduction in serious gastrointestinal events compared with non-selective NSAIDs, though the cardiovascular safety story has been more complicated and is the source of much of the regulatory and clinical history around the COX-2 class.

What it is used for

Osteoarthritis and rheumatoid arthritis — chronic pain and inflammation control. Ankylosing spondylitis — symptom control. Acute pain — short-course use for postoperative pain or musculoskeletal injury. Dysmenorrhoea — menstrual pain. Familial adenomatous polyposis — historical adjunctive use to reduce polyp burden, narrower today.

Choice of NSAID depends on the indication, the patient's cardiovascular and gastrointestinal risk, kidney function, age, and other drugs. For patients at higher gastrointestinal risk on chronic NSAID therapy, celecoxib is one option; alternatives include non-selective NSAIDs combined with proton pump inhibitor therapy.

Common adverse effects

NSAID-class effects mostly apply: dyspepsia, abdominal discomfort, fluid retention, hypertension elevation, kidney effects (particularly in older patients, those with reduced GFR, or those on ACE inhibitors and diuretics — the "triple whammy"), and rare hepatic injury. Cardiovascular risk is a class concern with COX-2 selective NSAIDs and with non-selective NSAIDs, and the absolute risk depends on dose, duration, and patient factors. Gastrointestinal ulceration and bleeding are reduced compared with non-selective NSAIDs but not eliminated.

Allergic-type reactions to celecoxib include rashes, occasional photosensitivity, and rare severe cutaneous reactions including Stevens-Johnson syndrome (very rare). Patients with aspirin-exacerbated respiratory disease (AERD, the asthma-NSAID-nasal polyp triad) should generally avoid all NSAIDs; COX-2 selectives are sometimes tolerated in this group but should not be assumed safe without specialist input.

The sulfa allergy story

Celecoxib's structure includes a sulfonamide group attached to a phenyl ring. It does not have the N4 arylamine that drives most antibiotic-type immune reactivity. The original product labelling, drafted in the era when "sulfa allergy" was treated as a class-wide concern, listed sulfa allergy as a contraindication — and that wording is still in force today.

Subsequent evidence — including series in which patients carrying sulfa allergy labels took celecoxib uneventfully — has shown low rates of cross-reaction, and the 2022 AAAAI/ACAAI drug allergy practice parameter lists celecoxib among the drugs with no or weak evidence of cross-reactivity after a sulfonamide antibiotic reaction. Regulators have not followed the specialists. The U.S. prescribing information revised in December 2024 still reads "contraindicated … in patients who have demonstrated allergic-type reactions to sulfonamides," and the UK and EU summaries of product characteristics retain equivalent wording. The reasoning is on antibiotic vs non-antibiotic sulfonamides; the broader picture is on cross-reactivity.

In current practice, most prescribers will consider celecoxib in patients with a documented mild sulfa antibiotic allergy where COX-2 selectivity is desired and the patient does not have other contraindications. Patients with severe past reactions to sulfa antibiotics — Stevens-Johnson syndrome, TEN, anaphylaxis — are managed cautiously and often offered a non-sulfonamide NSAID instead.

The label and the data disagree, and the label has not moved. This is one of the few places on this site where the regulatory position and the specialist position genuinely diverge, and it is worth stating plainly rather than smoothing over. The evidence for meaningful cross-reactivity between sulfa antibiotics and celecoxib is weak, and allergy guidelines say so. The contraindication nonetheless remains in the current U.S., UK, and EU product information. A prescriber who gives celecoxib to a patient with a recorded sulfa allergy is knowingly prescribing outside the label — defensible on the evidence, but their call to make, not something to be talked into.

A separate risk, often confused with the first. Celecoxib can cause serious skin reactions — Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS, and AGEP — in its own right. The label is explicit that these "can occur without warning and in patients without prior known sulfa allergy." This is a property of the drug, not a consequence of a sulfa allergy label, and it does not become more likely because you have one.

Interactions and cautions

Celecoxib is metabolised primarily by CYP2C9 and has interactions with drugs that share that pathway, including warfarin and fluconazole. Patients who are CYP2C9 poor metabolisers may have higher drug exposure. Routine NSAID interactions apply: caution with ACE inhibitors, ARBs, lithium, methotrexate, and certain antidepressants (with bleeding risk). Cardiovascular history, kidney function, and concomitant medications shape prescribing.

References

Celecoxib prescribing information (revised 12/2024). DailyMed, U.S. National Library of Medicine. dailymed.nlm.nih.gov
Khan DA, Banerji A, Blumenthal KG, et al. Drug allergy: a 2022 practice parameter update. J Allergy Clin Immunol. 2022;150(6):1333-93. www.jacionline.org
Shapiro LE, Knowles SR, Weber E, et al. Should celecoxib be contraindicated in patients who are allergic to sulfonamides? Drug Saf. 2001;24(4):239-47. pubmed.ncbi.nlm.nih.gov